Fungemias en pacientes con neoplasias hematológicas en Instituciones de Bogotá

dc.contributor.advisorCuervo Maldonado, Sonia Isabel
dc.contributor.authorVargas Espíndola, Luz Alejandra
dc.contributor.researchgroupGREICAH - Grupo en enfermedades infecciosas en cáncer y alteraciones hematológicasspa
dc.coverage.cityBogotá
dc.date.accessioned2021-09-08T03:29:24Z
dc.date.available2021-09-08T03:29:24Z
dc.date.issued2021
dc.description.abstractIntroducción: La incidencia de fungemias tiene alta morbimortalidad especialmente en pacientes con neoplasias hematológicas. El objetivo del estudio es describir las características epidemiológicas, clínicas y microbiológicas en pacientes adultos con fungemias con neoplasias. Materiales y métodos: En esta cohorte retrospectiva las historias clinicas y los reportes microbiologicos de todos los pacientes con neoplasias hematológicas y fungemias entre el 2012 al 2019 fueron identificados en instituciones de Bogotá. Resultados: Se identificaron 105 fungemias, edad promedio 48 años (DE 19.03); la mayoría en contexto de leucemias agudas (45%) y linfomas (37%). En 42% la enfermedad hematológica estaba en recaída/refractaria, 82% ECOG >3 y 35% recibían profilaxis antifúngica; 57% presentaron RAN <500 células/mm3, con una duración promedio de 21,78 días. Como factores de riesgo identificados 40% presentó infección relacionada con CVC, 17% mucositis y 13% uso de corticoides; 98% de los aislamientos correspondieron a levaduras y 2% a hongos miceliales; la mortalidad global fue del 50%. El total de los hongos miceliales identificados correspondieron al género Fusarium spp mientras el total de las levaduras 82% (86 pacientes) fueron por Candida spp y 18% por otras levaduras; 61% Candida no albicans de las cuales Candida tropicalis (28%) Candida parapsilosis 17% y Candida krusei 12% se identificaron. La probabilidad de supervivencia al día 30 para los pacientes con diagnóstico de leucemia fue del 59% (IC de 46-76) y en el grupo de linfoma/MM del 41% (IC 29-58), p=0.03. En el análisis univariado, la edad (HR 1,01 p=0.043), diagnóstico por grupo Linfoma/MM (HR 1,86 p=0,029), ingreso a UCI (HR 3,14 p=<0.01) y choque séptico (HR 1,38 p=<0.01) estuvieron estadísticamente asociados con incremento de la mortalidad. En el análisis multivariado el grupo diagnóstico (HR 1,72 p=0.04) y el ingreso a UCI (HR 3.08 p=<0.01) se relacionaron con mortalidad con significancia estadística. Conclusiones: las fungemias son un problema relevante en pacientes con neoplasias hematológicas con una mortalidad global significativa. El perfil epidemiológico ha cambiado con mayor frecuencia de aislamientos de C. tropicalis. Conocer los factores de riesgo de mortalidad es fundamental para un abordaje apropiado de estos pacientes. Palabras clave: Candida, fungemias, neoplasias hematológicas, candidemia (Texto tomado de la fuente)spa
dc.description.abstractIntroduction: The incidence of fungaemia has high morbimortality especially in patients with hematological malignancies. The goal of the study is to describe the epidemiological, clinical and microbiological characteristics in adult with fungemia and cancer Materials and methods: an observational retrospective cohort multicenter. We retrospectively reviewed charts of hospitalized patients with in which a documented fungaemia was diagnosed between 2012 and 2019 in hospitals in Bogota. Results: we recorded 105 fungal bloodstream infections. Average age 48 years (SD 19.03); most in the context of acute leukemias (45%) and lymphomas (37%). In 42% the hematologic disease was relapsed/refractory, 82% ECOG >3 and 35% were receiving antifungal prophylaxis; 57% presented RAN <500 cells/mm3, with an average duration of 21.78 days. The identified risk factors were, 40% had CVC-related infection, 17% had mucositis and 13% had corticosteroid use; 98% of the isolates corresponded to yeasts and 2% to moulds; overall mortality was 50%. The total of moulds identified corresponded to Fusarium spp while the total of yeasts 82% (86 patients) were Candida spp and 18% other yeasts; 61% non-albicans Candida of which Candida tropicalis (28%) Candida parapsilosis 17% and Candida krusei 12%. The probability of survival at day 30 for patients with a diagnosis of leukemia was 59% (CI 46-76) and in the lymphoma/MM group 41% (CI 29-58), p=0.03. In the univariate analysis, age (HR 1.01 p=0. 043), diagnosis by Lymphoma/MM group (HR 1.86 p=0.029), ICU admission (HR 3.14 p=<0.01) and septic shock (HR 1.38 p=<0.01) were statistically associated with increased mortality. In the multivariate analysis, the diagnostic group (HR 1.72 p=0.04) and admission to ICU (HR 3.08 p=<0.01) were statistically significantly associated with mortality. Conclusions: Fungaemia are a relevant problem in patients with hematological malignancies with significant overall mortality. The epidemiological profile has changed with a higher frequency of C. tropicalis isolates. Knowing the risk factors for mortality is essential for an appropriate approach to these patients. Key words: Candida, fungaemia, hematologic malignancies, candidemiaeng
dc.description.abstractilustraciones, gráficas, tablasspa
dc.description.degreelevelEspecialidades Médicasspa
dc.description.degreenameEspecialista en Medicina internaspa
dc.description.methodsCohorte retrospectiva multicéntricaspa
dc.description.researchareaInfecciones fúngicas en pacientes con cáncerspa
dc.format.extent58 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/80123
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentDepartamento de Medicina Internaspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Especialidad en Medicina Internaspa
dc.relation.references1. Cuervo-Maldonado SI, Bermúdez CD, Enciso L, Gómez-Rincón JC, Castillo JS, Sánchez R, et al. Guía de práctica clínica para el diagnóstico y el tratamiento de las infecciones bacterianas y micóticas en pacientes oncológicos mayores de 15 años con neutropenia febril posquimioterapia de alto riesgo. Rev Colomb Cancerol. octubre de 2014;18(4):186-96.spa
dc.relation.references2. Colombo AL, Cortes JA, Zurita J, Guzman-Blanco M, Alvarado Matute T, de Queiroz Telles F, et al. Recomendaciones para el diagnóstico de la candidemia en América Latina. Rev Iberoam Micol. julio de 2013;30(3):150-7.spa
dc.relation.references3. Kullberg BJ, Arendrup MC. Invasive Candidiasis. Campion EW, editor. N Engl J Med. 8 de octubre de 2015;373(15):1445-56.spa
dc.relation.references4. Pagano L, Mayor S. Invasive fungal infections in high-risk patients: report from TIMM-8 2017. Future Sci OA. julio de 2018;4(6):FSO307.spa
dc.relation.references5. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol Off J Am Soc Clin Oncol. 10 de 2018;36(14):1443-53.spa
dc.relation.references6. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 15 de febrero de 2011;52(4):e56-93.spa
dc.relation.references7. Nucci M, Queiroz‐Telles F, Tobón AM, Restrepo A, Colombo AL. Epidemiology of Opportunistic Fungal Infections in Latin America. Clin Infect Dis. septiembre de 2010;51(5):561-70.spa
dc.relation.references8. Cortés JA, Reyes P, Gómez C, Buitrago G, Leal AL. Fungal bloodstream infections in tertiary care hospitals in Colombia. Rev Iberoam Micol. abril de 2011;28(2):74-8.spa
dc.relation.references9. Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 de noviembre de 2005;41(10):1455-60.spa
dc.relation.references10. Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of invasive candidiasis. Clin Infect Dis Off Publ Infect Dis Soc Am. abril de 2012;54(8):1123-5.spa
dc.relation.references11. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 de febrero de 2016;62(4):e1-50.spa
dc.relation.references12. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. febrero de 2011;11(2):142-51.spa
dc.relation.references13. Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, et al. Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis. 1 de agosto de 2015;61(3):324-31.spa
dc.relation.references14. Bille J, Marchetti O, Calandra T. Changing face of health-care associated fungal infections. Curr Opin Infect Dis. agosto de 2005;18(4):314-9.spa
dc.relation.references15. Pemán J, Salavert M, Quindós G. Enfermedad fúngica invasiva por hongos filamentosos. Rev Iberoam Micol. octubre de 2014;31(4):211-2.spa
dc.relation.references16. Sifuentes-Osornio J, Corzo-León DE, Ponce-de-León LA. Epidemiology of Invasive Fungal Infections in Latin America. Curr Fungal Infect Rep. marzo de 2012;6(1):23-34.spa
dc.relation.references17. Almirante B, Rodríguez D, Cuenca-Estrella M, Almela M, Sanchez F, Ayats J, et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. mayo de 2006;44(5):1681-5.spa
dc.relation.references18. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. octubre de 2008;21(4):606-25.spa
dc.relation.references19. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis Off Publ Infect Dis Soc Am. 1 de octubre de 2005;41(7):975-81.spa
dc.relation.references20. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol. mayo de 2006;44(5):1782-7.spa
dc.relation.references21. Leroy O, Gangneux J-P, Montravers P, Mira J-P, Gouin F, Sollet J-P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. mayo de 2009;37(5):1612-8.spa
dc.relation.references22. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 de junio de 2009;48(12):1695-703.spa
dc.relation.references23. Lyon GM, Karatela S, Sunay S, Adiri Y, Candida Surveillance Study Investigators. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. abril de 2010;48(4):1270-5.spa
dc.relation.references24. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. enero de 2011;49(1):396-9.spa
dc.relation.references25. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. junio de 2008;112(11):2493-9.spa
dc.relation.references26. Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother. julio de 2010;65(7):1460-5.spa
dc.relation.references27. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. agosto de 2006;91(8):1068-75.spa
dc.relation.references28. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 12 de septiembre de 2020;71(6):1367-76.spa
dc.relation.references29. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): Stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 15 de octubre de 2009;115(20):4745-52.spa
dc.relation.references30. Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol. enero de 2012;50(1):50-5.spa
dc.relation.references31. Chen C-Y, Huang S-Y, Tsay W, Yao M, Tang J-L, Ko B-S, et al. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010. Int J Antimicrob Agents. diciembre de 2012;40(6):533-8.spa
dc.relation.references32. Criscuolo M, Marchesi F, Candoni A, Cattaneo C, Nosari A, Veggia B, et al. Fungaemia in haematological malignancies: SEIFEM-2015 survey. Eur J Clin Invest. 7 de marzo de 2019;e13083.spa
dc.relation.references33. Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, Kontoyiannis DP, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother. agosto de 2015;70(8):2362-8.spa
dc.relation.references34. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis Off Publ Infect Dis Soc Am. abril de 2012;54(8):1110-22.spa
dc.relation.references35. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis Off Publ Infect Dis Soc Am. septiembre de 1992;15(3):414-21.spa
dc.relation.references36. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. septiembre de 2005;49(9):3640-5.spa
dc.relation.references37. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis Off Publ Infect Dis Soc Am. 1 de julio de 2006;43(1):25-31.spa
dc.relation.references38. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis Off Publ Infect Dis Soc Am. junio de 2012;54(12):1739-46.spa
dc.relation.references39. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 de mayo de 2003;36(10):1221-8.spa
dc.relation.references40. Nucci M. Multicenter Survey of Invasive Fungal Infections (IFI) in Patient with Hematologic Malignancies and Hematopoietic Stem Cell Transplant Recipients (HSCT) in Brazil. En Idsa; 2008 [citado 25 de febrero de 2019]. Disponible en: https://idsa.confex.com/idsa/2008/webprogram/Paper26789.htmlspa
dc.relation.references41. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. marzo de 1998;104(3):238-45.spa
dc.relation.references42. Cornely OA, Hoenigl M, Lass‐Flörl C, Chen SC ‐A., Kontoyiannis DP, Morrissey CO, et al. Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. 19 de julio de 2019;myc.12960.spa
dc.relation.references43. Ministerio de Salud de Colombia. Resolución No 008430 de 1993.spa
dc.relation.references44. Manzini JL. Declaración de helsinki: principios éticos para la investigación médica sobre sujetos humanos. Acta Bioethica [Internet]. diciembre de 2000spa
dc.relation.references45. Fisher RA. XV.—The Correlation between Relatives on the Supposition of Mendelian Inheritance. Trans R Soc Edinb. 1919;52(2):399-433.spa
dc.relation.references46. Tukey JW. Comparing Individual Means in the Analysis of Variance. Biometrics. junio de 1949;5(2):99.spa
dc.relation.references47. Sprent P, Smeeton NC. Applied nonparametric statistical methods. 4th ed. Boca Raton: Chapman & Hall/CRC; 2007. 530 p. (Texts in statistical science).spa
dc.relation.references48. Wilcoxon F. Individual Comparisons by Ranking Methods. Biom Bull. diciembre de 1945;1(6):80.spa
dc.relation.references49. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. junio de 1958;53(282):457-81.spa
dc.relation.references50. Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B Methodol. enero de 1972;34(2):187-202.spa
dc.relation.references51. Koller, D., & Sahami. Toward optimal feature selection. 1996.spa
dc.relation.references52. Cortés JA, Reyes P, Gómez CH, Cuervo SI, Rivas P, Casas CA, et al. Clinical and epidemiological characteristics and risk factors for mortality in patients with candidemia in hospitals from Bogotá, Colombia. Braz J Infect Dis. noviembre de 2014;18(6):631-7.spa
dc.relation.references53. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, et al. Risk Factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis Off Publ Infect Dis Soc Am. 15 de noviembre de 2001;33(10):1676-81.spa
dc.relation.references54. Janum S, Afshari A. Central venous catheter (CVC) removal for patients of all ages with candidaemia. Cochrane Database Syst Rev. 11 de julio de 2016;7:CD011195.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseReconocimiento 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/spa
dc.subject.ddc610 - Medicina y saludspa
dc.subject.lembEnfermedades de la sangrespa
dc.subject.lembHematologic diseaseseng
dc.subject.lembHematologíaspa
dc.subject.lembHematologyeng
dc.subject.proposalCandidaspa
dc.subject.proposalFungemiaspa
dc.subject.proposalNeoplasia hematológicaspa
dc.subject.proposalCandidemiaspa
dc.subject.proposalFungaemiaeng
dc.subject.proposalCancerspa
dc.subject.proposalHematologic malignancieseng
dc.titleFungemias en pacientes con neoplasias hematológicas en Instituciones de Bogotáspa
dc.title.translatedFungaemia in patients with hematological malignancies in Bogotaeng
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
1014194537.2021.pdf
Tamaño:
1.42 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Especialidad Médica en Medicina interna

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
3.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: